Skin in the Game: Tackling Atopic Dermatitis with Topical Treatment : Episode 4

Long-Term Use of Topical Treatments in Atopic Dermatitis

March 4, 2025

Opinion

Video

Panelists discuss how the newer topical agents (PDE4 inhibitors, JAK inhibitors) demonstrate comparable efficacy to midpotency corticosteroids but with improved safety profiles, lacking steroid-related adverse effects such as skin atrophy, hypothalamic-pituitary-adrenal axis suppression, and tachyphylaxis when used long term.

EP: 1.Diagnosing and Defining Severity of Atopic Dermatitis

EP: 2.Older Approaches to Topical Treatment of Atopic Dermatitis

EP: 3.New Nonsteroidal Topical Treatment Options for Atopic Dermatitis

Now Viewing

EP: 4.Long-Term Use of Topical Treatments in Atopic Dermatitis

EP: 5.Addressing Itch and Quality of Life for Patients With Atopic Dermatitis

EP: 6.Importance of Patient Education and Multidisciplinary Communication

Video content above is prompted by the following:

How do the long-term efficacy and safety profiles of these newer agents compare with topical corticosteroids?

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!